GlaxoSmithKline Pharma Q4 Results: Profit Up 36% At Rs 263 Crore
The board of GlaxoSmithKline Pharmaceuticals proposed a final dividend of Rs 42 per share for FY25.
(Photo source: Envato)
GlaxoSmithKline Pharmaceuticals Ltd. reported a 36% increase in consolidated net profit to Rs 263 crore for the quarter ended March 31, 2025, up from Rs 194 crore in the same period last year.
Revenue rose 5% to Rs 974 crore in the January-March quarter, compared to Rs 930 crore in the year-ago period, according to an exchange filing on Tuesday.
The pharmaceutical firm recorded a consolidated net profit of Rs 927 crore for fiscal 2025, a sharp rise from Rs 590 crore in the preceeding year.
Annual revenue also saw a rise to Rs 3,749 crore in fiscal 2025 from Rs 3,454 crore in the previous financial year.
The board of GlaxoSmithKline Pharmaceuticals proposed a final dividend of Rs 42 per share for FY25.
"Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professionals' engagement and rapid digital acceleration," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said.
This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for customers, he added.
"We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY26, we will continue to focus on our innovative portfolio through the launch of our oncology assets," Akshikar said.
The company is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer, he added.
(With PTI Inputs)
